ATE557101T1 - Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum - Google Patents

Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum

Info

Publication number
ATE557101T1
ATE557101T1 AT05723099T AT05723099T ATE557101T1 AT E557101 T1 ATE557101 T1 AT E557101T1 AT 05723099 T AT05723099 T AT 05723099T AT 05723099 T AT05723099 T AT 05723099T AT E557101 T1 ATE557101 T1 AT E557101T1
Authority
AT
Austria
Prior art keywords
methods
compositions
subject
tolerant phenotype
transplantation
Prior art date
Application number
AT05723099T
Other languages
English (en)
Inventor
Elaine Mansfield
Minnie Sarwal
Sophie Brouard
Jean-Paul Soulilou
Original Assignee
Univ Leland Stanford Junior
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior, Inst Nat Sante Rech Med filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE557101T1 publication Critical patent/ATE557101T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)
AT05723099T 2004-01-21 2005-01-20 Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum ATE557101T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US53843904P 2004-01-21 2004-01-21
US57147104P 2004-05-14 2004-05-14
PCT/US2005/004799 WO2005070086A2 (en) 2004-01-21 2005-01-20 Methods and compositions for determining a graft tolerant phenotype in a subject

Publications (1)

Publication Number Publication Date
ATE557101T1 true ATE557101T1 (de) 2012-05-15

Family

ID=34811352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05723099T ATE557101T1 (de) 2004-01-21 2005-01-20 Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum

Country Status (5)

Country Link
US (2) US8932808B1 (de)
EP (1) EP1718768B1 (de)
AT (1) ATE557101T1 (de)
CA (2) CA2553551C (de)
WO (1) WO2005070086A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE46843E1 (en) 2005-03-14 2018-05-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for evaluating graft survival in a solid organ transplant recipient
EP2604703B1 (de) * 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Verfahren zur Bewertung der Haltbarkeit eines Pfropfs im Körper eines Empfängers fester Organtransplantate
EP2369016A1 (de) 2006-05-25 2011-09-28 Institut National de la Santé et de la Recherche Médicale (INSERM) Verfahren zur Diagnose und Behandlung von Transplantatabstoßungen und Entzündungszuständen
US20080233573A1 (en) * 2006-08-28 2008-09-25 Kathleen Storm Gene expression profiling for identification, monitoring and treatment of transplant rejection
US20080131441A1 (en) * 2006-09-26 2008-06-05 Manikkam Suthanthiran Methods of Using FOXP3 Levels to Predict the Outcome of Organs Undergoing Acute Rejection
EP1990425A1 (de) * 2007-05-10 2008-11-12 Tcland R Diagnose von Immuntransplantatstoleranz
EP2088205A1 (de) 2008-02-11 2009-08-12 Institut National De La Sante Et De La Recherche Medicale (Inserm) PSMB10: Diagnosemarker und therapeutisches Target für chronische Abstoßung
WO2010021696A1 (en) 2008-08-18 2010-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
US20120046181A1 (en) * 2008-12-19 2012-02-23 Chu Nantes Biomarkers for the Diagnosis of Renal Allograft and Kidney Status
ES2492498T3 (es) 2009-01-15 2014-09-09 The Board Of Trustees Of The Leland Stanford Junior University Panel de biomarcadores para el diagnóstico y la predicción de rechazo de injerto
US9290813B2 (en) 2009-12-02 2016-03-22 The Board Of Trustees Of The Leland Stanford Junior University Biomarkers for determining an allograft tolerant phenotype
CA2794255C (en) 2010-03-25 2020-01-14 The Board Of Trustees Of The Leland Stanford Junior University Protein and gene biomarkers for rejection of organ transplants
WO2012139051A2 (en) 2011-04-06 2012-10-11 The Board Of Trustees Of The Leland Stanford Junior University Autoantibody biomarkers for iga nephropathy
US20140072971A1 (en) * 2012-08-30 2014-03-13 Abbott Laboratories Prame detection assays
CA2961340C (en) 2014-09-26 2023-10-17 Somalogic, Inc. Cardiovascular risk event prediction and uses thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994076A (en) 1997-05-21 1999-11-30 Clontech Laboratories, Inc. Methods of assaying differential expression
US20030104371A1 (en) 1997-09-24 2003-06-05 Strom Terry B. Methods of evaluating transplant rejection
US6607879B1 (en) * 1998-02-09 2003-08-19 Incyte Corporation Compositions for the detection of blood cell and immunological response gene expression
EP1069432B1 (de) 1998-03-31 2008-05-21 Asahi Kasei Pharma Corporation VERFAHREN ZUR UNTERSUCHUNG DER IgA-NEPHROPATHIE
WO2002092124A1 (en) 2001-05-11 2002-11-21 Wyeth Methods for diagnosing and treating ischemia and reperfusion injury and compositions thereof
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
DE60335652D1 (de) 2002-11-21 2011-02-17 Genzyme Corp Verwendung eines diamidderivats zur verhinderung der chronischen transplantatabstossung
AU2004213839B2 (en) 2003-02-14 2010-08-12 Beth Israel Deaconess Medical Center, Inc. Predicting graft rejection
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7648825B2 (en) 2003-06-20 2010-01-19 University Of Florida Research Foundation, Inc. Biomarkers for differentiating between type 1 and type 2 diabetes
EP1694860A2 (de) 2003-12-03 2006-08-30 Novartis AG Biomarker für die transplantatabstossung
US20070232658A1 (en) 2004-04-08 2007-10-04 Jurgen Wagner Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction
US7820382B2 (en) 2004-08-03 2010-10-26 Bauer A Robert Method for the early detection of breast cancer, lung cancer, pancreatic cancer and colon polyps, growths and cancers as well as other gastrointestinal disease conditions and the preoperative and postoperative monitoring of transplanted organs from the donor and in the recipient and their associated conditions related and unrelated to the organ transplantation
EP2604703B1 (de) * 2005-03-14 2017-02-01 The Board of Trustees of the Leland Stanford Junior University Verfahren zur Bewertung der Haltbarkeit eines Pfropfs im Körper eines Empfängers fester Organtransplantate
US7666596B2 (en) 2005-05-23 2010-02-23 University Of Alberta Tissue rejection
EP1731620A1 (de) 2005-06-07 2006-12-13 Institut National De La Sante Et De La Recherche Medicale (Inserm) Methode zur Diagnose von Immun-Transplantatstoleranz
ES2624863T3 (es) 2005-06-08 2017-07-17 Millennium Pharmaceuticals, Inc. Métodos para identificación, evaluación, y tratamiento de pacientes con terapia de cáncer
US20070134728A1 (en) 2005-10-25 2007-06-14 Renovar Incorporated Systems and methods for characterizing conditions and diseases associated with organ transplantation and organ health
EP1989554A1 (de) 2006-02-06 2008-11-12 Rappaport Family Institute For Research in the Medical Sciences Verfahren und kit zur diagnose von t1dm
GB0605217D0 (en) 2006-03-15 2006-04-26 Novartis Ag Method and compositions for assessing acute rejection
GB0607943D0 (en) 2006-04-21 2006-05-31 Novartis Ag Biomarkers for chronic transplant dysfunction
WO2007124578A1 (en) 2006-04-27 2007-11-08 Universite De Montreal Assessment and reduction of risk of graft-versus-host disease
WO2008084331A2 (en) 2006-06-21 2008-07-17 Hopitaux Universitaires De Geneve Biomarkers for renal disorders
EP2049713A4 (de) 2006-07-21 2010-06-16 Univ Alberta Gewebeabstossung
US20080233573A1 (en) 2006-08-28 2008-09-25 Kathleen Storm Gene expression profiling for identification, monitoring and treatment of transplant rejection
AU2009253696A1 (en) 2008-05-30 2009-12-03 The University Of British Columbia Methods of diagnosing rejection of a kidney allograft using genomic or proteomic expression profiling
ES2402483T3 (es) 2008-06-02 2013-05-06 Eisai R&D Management Co., Ltd. Método de detección y kit de detección de nefropatía por lgA
WO2010021696A1 (en) 2008-08-18 2010-02-25 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for determining a graft tolerant phenotype in a subject
KR100928403B1 (ko) 2008-10-01 2009-11-26 경북대학교 산학협력단 티지비엠 신증의 진단용 조성물 및 키트
AU2011253385B2 (en) 2010-05-13 2016-11-03 Rowan University Diagnostic autoantibody profiles for the detection and diagnosis of neurodegenerative diseases

Also Published As

Publication number Publication date
EP1718768A4 (de) 2007-10-17
CA2553551C (en) 2020-12-15
WO2005070086A3 (en) 2006-09-14
WO2005070086A2 (en) 2005-08-04
CA2957704A1 (en) 2005-08-04
CA2553551A1 (en) 2005-08-04
EP1718768B1 (de) 2012-05-09
EP1718768A2 (de) 2006-11-08
US20140206566A1 (en) 2014-07-24
US8932808B1 (en) 2015-01-13

Similar Documents

Publication Publication Date Title
Conway et al. Kidney single-cell atlas reveals myeloid heterogeneity in progression and regression of kidney disease
ATE557101T1 (de) Verfahren und zusammensetzungen zur bestimmung eines transplantationstoleranten phänotyps in einem individuum
Corbin et al. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity
Bermingham et al. Vicariance biogeography in the Pleistocene and speciation in North American wood warblers: a test of Mengel's model.
Bahram et al. A single European aspen (Populus tremula) tree individual may potentially harbour dozens of Cenococcum geophilum ITS genotypes and hundreds of species of ectomycorrhizal fungi
ATE428931T1 (de) Verfahren zur durchführung von vollbluttests
WO2006099421A3 (en) Methods and compositions for evaluating graft survival in a solid organ transplant recipient
WO2007103374A3 (en) Toxicity screening methods
EP2212700B8 (de) Verfahren zur beurteilung von kolorektalem krebs anhand einer stuhlprobe durch verwendung einer marker-kombination aus calprotectin und einem hämoglobin/haptoglobin-komplex
ATE469656T1 (de) Verfahren und reagentien zur diagnose von hantavirusinfektionen
WO2008033427A3 (en) Compositions and methods for detection of lysosomal storage disease
Zhong et al. Correlation between imatinib trough concentration and efficacy in Chinese chronic myelocytic leukemia patients
WO2011133770A3 (en) Salivary protein markers for detection of breast cancer
Jo et al. Impact of mouse contamination in genomic profiling of patient-derived models and best practice for robust analysis
Perez‐Lamarque et al. Analysing diversification dynamics using barcoding data: The case of an obligate mycorrhizal symbiont
MX2021009264A (es) Metodo de caracterizacion de particulas visibles y/o subvisibles en agentes biologicos.
Piano Mortari et al. Functional CVIDs phenotype clusters identified by the integration of immune parameters after BNT162b2 boosters
MX2009006744A (es) Panel de padecimiento cardiovascular autoinmune y metodos de utilizacion del mismo.
Ilhan et al. Leukemic stem cells shall be searched in the bone marrow before “tyrosine kinase inhibitor‐discontinuation” in chronic myeloid leukemia
Lovell et al. Cryptic speciation in the Warbling Vireo (Vireo gilvus)
ATE456801T1 (de) Verfahren zur messung immunsuppressiver tacrolimus-, sirolimus- und cyclosporin-a- komplexe in einer blutprobe
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
FI20040255A7 (fi) Menetelmä pre-eklampsian riskin havaitsemiseksi
WO2008147206A3 (en) Means and methods for classifying samples of multiple sclerosis patients
WO2006103639A3 (en) Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals